SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
Related Experiment Video
Updated: Dec 6, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Abstract:
An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of Coronavirus Disease-2019 (COVID-19), a respiratory disease, has infected over 34,000,000 people since the end of 2019, killed over 1,000,000, and caused worldwide social and economic disruption. Due to the mechanisms of SARS-CoV-2 infection to host cells and its pathogenesis remain largely unclear, there are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention. Besides severe respiratory and systematic symptoms, several comorbidities may also increase risk of fatal disease outcome. Therefore, it is required to investigate the impacts of COVID-19 on pre-existing diseases of patients, such as cancer and other infectious diseases. In the current study, we have reported that SARS-CoV-2 encoded proteins and some anti-COVID-19 drugs currently used are able to induce lytic reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV), one of major human oncogenic viruses through manipulation of intracellular signaling pathways. Our data indicate that those KSHV+ patients especially in endemic areas exposure to COVID-19 or undergoing the treatment may have increased risks to develop virus-associated cancers, even after they have fully recovered from COVID-19.
Insights
Coronavirus Disease-2019 (COVID-19) infection and treatments may reactivate Kaposi's sarcoma-associated herpesvirus (KSHV). This increases cancer risk in KSHV-positive patients, even after COVID-19 recovery.
Area of Science:
- Virology
- Oncology
- Infectious Diseases
Background:
- The novel coronavirus SARS-CoV-2 causes COVID-19, a global pandemic with significant mortality and socioeconomic impact.
- Pathogenesis and host cell infection mechanisms of SARS-CoV-2 are not fully understood, lacking specific antiviral treatments and vaccines.
- Comorbidities can worsen COVID-19 outcomes, necessitating research into its effects on pre-existing conditions like cancer and other infections.
Approach:
- Investigated the impact of SARS-CoV-2 proteins and anti-COVID-19 drugs on Kaposi's sarcoma-associated herpesvirus (KSHV).
- Examined the manipulation of intracellular signaling pathways by SARS-CoV-2 and related drugs.
- Assessed the risk of virus-associated cancers in KSHV-positive individuals exposed to COVID-19 or its treatments.
Key Points:
- SARS-CoV-2 proteins and certain anti-COVID-19 medications can induce lytic reactivation of KSHV, a human oncogenic virus.
- Reactivation occurs through the manipulation of intracellular signaling pathways.
- KSHV-positive patients exposed to COVID-19 or its treatments face elevated risks for developing virus-associated cancers.
Conclusions:
- COVID-19 infection and its treatments pose a potential risk for KSHV reactivation.
- This reactivation may lead to an increased incidence of KSHV-associated malignancies.
- KSHV-positive individuals, particularly those in endemic areas, require careful monitoring for cancer development post-COVID-19 exposure or treatment.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers
Viral Replication: Lytic Cycle
Viral Mutations
Induced Pluripotent Stem Cells
Somatic...
Viral Replication: Lysogenic Cycle

